New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca²⁺ channel blocker

Bibliography

• VARON J, MARIK PE: Clinical review: the management of hypertensive crises. Crit. Care (2003) 7(5):374-384.
   PubMed Web of Science ®Google Scholar
• ERICSSON H, FAKT C, JOLIN-MELLGARD A et al.: Clinical and pharmacokinetic results with a new acting-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br. J. Clin. Pharmacol. (1999) 47:531-538.
   PubMed Web of Science ®Google Scholar
• ERICSSON H, THOLANDER B, BJORKMAN JA, NORDLANDER M, REGARDH CG: Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab. Dispos. (1999) 27:558-564.
   PubMed Web of Science ®Google Scholar
• GODFRAIND T, SALOMONE S, DESSY C, VERHELT B, DION R, SCHOEVAERTS JC: Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J. Cardiovasc. Pharmacol. (1992) 205:S34-S41.
   PubMed Web of Science ®Google Scholar
• NORDLANDER M, SJOQUIST PO, ERICSSON H, RYDEN L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc. Drug Rev. (2004) 22(3):227-250.
   PubMed Web of Science ®Google Scholar
• SEGAWA D, SJOQUIST PO, NORDLANDER M, WANG QD, GONON A, RYDEN L: Cardiac inotropic versus chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine. Eur. J. Pharmacol. (1999) 10;380(2-3):123-128.
   Web of Science ®Google Scholar
• ERICSSON H, THOLANDER B, REGARDH CG: In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolized by esterases, in different animal species and man. Eur. J. Pharm. Sci. (1999) 8:29-37.
   PubMed Web of Science ®Google Scholar
• ERICSSON H, SCHWIELER J, LINDMARK B, LöFDAHL P, THULIN T, REGÅRDH C: Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients. Chirality (2001) 13:130-134.
   PubMed Web of Science ®Google Scholar
• ZHANG JG, DEHAL SS, HO T et al.: Human cytochrome P450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab. Dispos. (2006) 34:734-737.
   PubMed Web of Science ®Google Scholar
• WANG QD, SAGAWA D, ERICSSON H, SJOQUIST PO, JOHANSON L, RYDEN L: Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: Part I. J. Cardiovasc. Pharmacol. (2002) 40(2):228-234.
   PubMed Web of Science ®Google Scholar
• SAGAWA D, SJOQUIST PO, WANG QD, GONON A, RYDEN L: Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II. J. Cardiovasc. Pharmacol. (2002) 40(3):339-345.
   PubMed Web of Science ®Google Scholar
• GOURINE AV, PERNOW J, POPUTNIKOV DM, SJOQUIST PO: Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide. J. Cardiovasc. Pharmacol. (2002) 40:564-570.
   PubMed Web of Science ®Google Scholar
• ODENSTEDT J, MANSSON C, GRIP L: Failure to demonstrate myocardial protective effects of the ultra short-acting calcium antagonist clevidipine in a closed-chest reperfusion porcine model. J. Cardiovasc. Pharmacol. (2004) 44:407-415.
   PubMed Web of Science ®Google Scholar
• STEPHENS CT, JANDHYALA BS: Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin. Exp. Hypertens. (2002) 24:301-313.
   PubMed Web of Science ®Google Scholar
• ADAMS HP, ADAMS RJ, BROTT T et al.: Guidelines for the early management of patients with ischemic stroke. A scientific statement from the Stroke Council of the American Stroke Association. Stroke (2003) 34:1056.
   PubMed Web of Science ®Google Scholar
• NORDLANDER M, BJORKMAN JA, REGARDH CG, THALEN P: Pharmacokinetics and hemodynamic effects of an ultrashort-acting calcium antagonist. Br. J. Anaesth. (1996) 76(Suppl. 1):A24.
   Google Scholar
• SCHWIELER JH, ERICSSON H, LOFDAHL P, THULIN T, KAHAN T: Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J. Cardiovasc. Pharmacol. (1999) 34(2):268-274.
   Google Scholar
• BAILEY JM, LU W, LEVY JH et al.: Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology (2002) 96:1086-1094.
   PubMed Web of Science ®Google Scholar
• LEVY JH, MANCAO MY, GITTER R, GRIGORE AM, NEWMAN MF: Clevidipine effectively and rapidly controls elevated blood pressure preoperatively in cardiac surgery patients. Anesthesiology (2005) 103:A354 (Abstract).
   Google Scholar
• SINGLA N, WARLTIER DC, LUMB PD, SLADEN RN: Clevidipine is effective in rapidly controlling elevated blood pressure postoperatively in cardiac surgery patients. Anesthesiology (2005) 103:A292 (Abstract).
   Google Scholar
• POWROZNYK AV, VUYLSTEKE A, NAUGHTON C et al.: Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur. J. Anaesthesiol. (2003) 20(9):697-703.
   PubMed Web of Science ®Google Scholar
• KIELER-JENSEN N, JOLIN-MELLGÅRD Å, NORDLANDER M, RICKSTEN SE: Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol. Scand. (2000) 44:186-193.
   PubMed Web of Science ®Google Scholar
• ARONSON S, DYKE CM, KEREIAKES D, CHEUNG A, NEWMAN M: Blood pressure control with clevidipine compared to nitroglycerin in the treatment of perioperative hypertension: primary results from the randomized ECLIPSE trial. J. Am. Coll. Cardiol. (2007) 49:A315-419A.
   Google Scholar
• ELLIOT WJ: Clinical features in the management of selected hypertensive emergencies. Prog. Cardiovasc. Dis. (2006) 48:316-325.
   PubMed Web of Science ®Google Scholar
• MURPHY MB, MURRAY C, SHORTEN GD: Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N. Engl. J. Med. (2001) 22;345(21):1548-1557.
   Google Scholar
• FISCHELL TA, MAHESHWARI A: Current applications for nicardipine in invasive and interventional cardiology. J. Invasive Cardiol. (2004) 16(8):428-432.
   PubMedGoogle Scholar
• GROSSMAN E, MESSERLI FH, GRODZICKI T et al.: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA (1996) 276:1328-1331.
   PubMed Web of Science ®Google Scholar
• ERSTAD BL, BARLETTA JF: Treatment of hypertension in the perioperative patient. Ann. Pharmacother. (2000) 34:66-79.
   PubMed Web of Science ®Google Scholar
• GRADMAN AH, VIVAS Y: New drugs for hypertension: what do they offer? Curr. Hypertens. Rep. (2006) 8(5):425-432.
   PubMed Web of Science ®Google Scholar
• PRYS-ROBERTS C, MELOCHE R, FOEX P: Studies of anaesthesia in relation to hypertension. I. Cardiovascular responses of treated and untreated patients. Br. J. Anaesth. (1971) 43:122.
   PubMed Web of Science ®Google Scholar
• HOWELL SJ, HEMMING AE, ALLMAN KG, GLOVER L, SEAR JW, FOEX P: Predictors of postoperative myocardial ischemia. The role of intercurrent arterial hypertension and other cardiovascular risk factors. Anaesthesia (1997) 52:107-111.
   PubMed Web of Science ®Google Scholar
• CURRAN MP, ROBINSON DM, KEATING GM: Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications. Drugs (2006) 66(13):1755-1782.
   PubMed Web of Science ®Google Scholar